189041-55-2

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, [6-amino-5-[[(1,1-dimethylethoxy)carbonyl]amino]hexyl]-, phenylmethyl ester, (S)is used as a pharmaceutical compound for its potential therapeutic effects. Its unique structure and functional groups may contribute to its biological activity, making it a promising candidate for further investigation and development.
Used in Drug Synthesis:
As a precursor in the synthesis of other pharmaceutical compounds, Carbamic acid, [6-amino-5-[[(1,1-dimethylethoxy)carbonyl]amino]hexyl]-, phenylmethyl ester, (S)can be utilized to create a variety of drug molecules with potential therapeutic applications.
Used in Chemical and Biological Research:
Carbamic acid, [6-amino-5-[[(1,1-dimethylethoxy)carbonyl]amino]hexyl]-, phenylmethyl ester, (S)serves as a valuable research tool in chemical and biological studies. Its unique properties and potential biological activities make it an interesting subject for further investigation, contributing to the understanding of its mechanisms of action and potential applications in drug discovery.

Upstream product

• 55592-81-9 N^ε-(benzyloxycarbonyl)-N^α-(tert-butoxycarbonyl)-L-lysinamide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 73548-77-3 Boc-L-Lys(Z)-OMe 
• 82689-20-1 N⁶-benzyloxycarbonyl-N²-tert-butoxycarbonyl-L-lysinol 
• 126583-16-2 Boc-Lys(Z)-OCOOEt 
• 2389-45-9 Boc-Lys(Z)-OH 
• 244778-27-6 (5-tert-butoxycarbonylamino-5-cyano-pentyl)-carbamic acid benzyl ester 
• 189041-54-1 [(S)-5-benzyloxycarbonylamino-1-(1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl)-pentyl]-carbamic acid tert-butyl ester 

Downstream Products

• 310870-55-4 ((S)-5,6-diaminohexyl)carbamic acid benzyl ester 
• 1160939-44-5 (4-{2-[(Z)-3,5-diamino-6-chloro-pyrazine-2-carbonylimino]-imidazolidin-4-yl}-butyl)-carbamic acid benzyl ester 
• 1160754-79-9 {2-[4-(4-methoxyphenyl)butyrylamino]ethyl}carbamic acid tert-butyl ester 
• 1160754-80-2 {2-[4-(4-methoxyphenyl)butylamino]ethyl}carbamic acid tert-butyl ester 
• 1196038-61-5 ((S)-5-[2-(4-benzyloxy-phenyl)-acetylamino]-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-pentyl)-carbamic acid tert-butyl ester 
• 1196038-89-7 ((S)-5-benzyloxycarbonylamino-1-{[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-methyl}-pentyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Synthesis and DNA-damaging properties of cisplatin-N-mustard conjugates

We report the synthesis of two novel cisplatin-N-mustard conjugates. In these compounds two potentially DNA-damaging molecules are combined and are separated by a spacer containing either one or four ethylene glycol units. We have shown that these conjuga

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Organic Compounds

A compound of Formula I in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Solid-phase synthesis of oligourea peptidomimetics

A procedure for the solid-phase synthesis of oligourea peptidomimetics starting from Boc-protected monomers is described. The compounds are prepared on Tentagel resin and can be obtained selectively rather as the C-terminal free acids with UV irradiation

Synthesis of chiral triamines and diamines from amino acids

Selectively protected (2S)-1,2,6-triaminohexane 4 was prepared from L-lysine by reduction of the amino acid, replacement of the hydroxy group by an azido group and selective reduction. Following the same method vicinal diamines 11 and 13 bearing a third functional group were synthesized from L-glutamic acid.